Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alnylam Pharmaceuticals IncfiledCriticalAlnylam Pharmaceuticals Inc
Publication of AR096390A1publicationCriticalpatent/AR096390A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Se relaciona con agentes de ARNi, por ejemplo, agentes de ARNi de doble hebra, que se dirigen contra el gen de Serpina1, y métodos para usar dichos agentes de ARNi para inhibir la expresión de Serpina1 y métodos para tratar a sujetos que tienen una enfermedad asociada a Serpina1, tal como un trastorno de hígado. Composición farmacéutica; vector; célula; método para reducir la acumulación de Serpina1.It relates to RNAi agents, for example, double-stranded RNAi agents, which are directed against the Serpina1 gene, and methods for using said RNAi agents to inhibit Serpina1 expression and methods for treating subjects who have a disease. associated with Serpina1, such as a liver disorder. Pharmaceutical composition; vector; cell; method to reduce the accumulation of Serpine1.
ARP140102031A2013-05-222014-05-22
COMPOSITIONS OF ARNi DE SERPINA1 AND ITS METHODS OF USE
AR096390A1
(en)
COMPOSITIONS OF ARNi AGAINST FACTOR XII (HAGEMAN FACTOR) (F12), CALICREIN B, PLASMATIC (FLETCHER FACTOR) 1 (KLKB1), AND QUININOGEN 1 (KNG1) AND METHODS OF USE OF THE SAME